Edgewise Therapeutics says it will move its experimental heart drug into a late-stage, registrational clinical trial after updated results from its ongoing mid-stage study came back positive. The drug targets hypertrophic cardiomyopathy, a genetic condition in which the heart muscle thickens abnormally, making it harder for the heart to pump blood — a disease that can cause chest pain, breathlessness, and sudden cardiac events.
According to Endpoints News, the biotech announced the decision Tuesday, framing the Phase 2 update as sufficient evidence to proceed toward the kind of large trial regulators typically require before approving a new medicine.
The path forward is not without complications, however. According to BioPharma Dive, the results leave it "somewhat unclear" how Edgewise's drug — known as EDG-7500 — actually differs from treatments for the same condition already on the market. Bristol Myers Squibb and Cytokinetics both have approved hypertrophic cardiomyopathy medicines, meaning Edgewise will need to carve out a compelling case for its drug in an increasingly crowded field.
That distinction matters enormously for patients, doctors, and investors alike: a drug that works similarly to existing options may struggle to win prescriptions or reimbursement, while one that proves meaningfully better — or that helps patients who don't respond to current drugs — could become a significant new option for the hundreds of thousands of people living with this condition.